Upadacitinib (Rinvoq®) accepted for restricted use within NHSScotland

This JAK inhibitor is recommended as monotherapy or in combination with methotrexate for treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to ≥2 conventional DMARDs, given either alone or in combination.

Source:

Scottish Medicines Consortium